Press release
Hyperphosphatemia Treatment Market Analysis, Trends, Growth, Research And Forecast 2033
Hyperphosphatemia Treatment Market
The Business Research Company offers in-depth market insights through Hyperphosphatemia Treatment Global Market Report 2024, providing businesses with a competitive advantage by thoroughly analyzing the market structure, including estimates for numerous segments and sub-segments.
Market Size And Growth Forecast:
The hyperphosphatemia treatment market size has grown rapidly in recent years. It will grow from $4.1 billion in 2023 to $4.61 billion in 2024 at a compound annual growth rate (CAGR) of 12.6%. The growth in the historic period can be attributed to increased incidence of chronic kidney disease (ckd), growth in aging population, high prevalence of diabetes and hypertension, expansion of dialysis patient population, advances in medical research and diagnosis of hyperphosphatemia.
The hyperphosphatemia treatment market size is expected to see rapid growth in the next few years. It will grow to $7.54 billion in 2028 at a compound annual growth rate (CAGR) of 13.1%. The growth in the forecast period can be attributed to rise in lifestyle-related diseases contributing to hyperphosphatemia, continued growth in aging demographics, increasing awareness and diagnosis of hyperphosphatemia, expansion of emerging markets with high disease burden, higher prescription share of calcium-based phosphate binders in emerging countries. Major trends in the forecast period include advancements in hyperphosphatemia treatment technologies, integration of telehealth and remote patient monitoring, collaborations and partnerships for research and development, focus on patient education and lifestyle management in hyperphosphatemia, development of novel phosphate binders and therapies.
Get Free Sample Of This Report-
https://www.thebusinessresearchcompany.com/sample.aspx?id=5852&type=smp
Market Segmentation:
The hyperphosphatemia treatment market covered in this report is segmented -
1) By Product: Sevelamer, Calcium-Based Phosphate Binders, Iron-Based Phosphate Binders, Lanthanum Carbonate, Other products
2) By Distribution channel: Hospital Pharmacy, Retail Pharmacy, Online stores
Major Driver - Sustainable Growth Of Hyperphosphatemia Treatment Market Amid Rising Chronic Disease Prevalence
The increase chronic diseases among patients is driving the growth of the hyperphosphatemia treatment market. Chronic diseases are non-communicable and require long-term care. A vast majority of chronic diseases can be categorized as cardiovascular diseases, chronic kidney disease, chronic respiratory conditions, hyperparathyroidism, diabetes, and cancer. For instance, in September 2023, according to the World Health Organization, a Switzerland-based specialized agency of the United Nations, there were 41 million deaths, which is 74% of those caused by non-communicable diseases (NCDs) or chronic diseases every year globally. Furthermore, in February 2023, according to SingleCare Services LLC, a US-based healthcare savings platform, the prevalence of kidney diseases is increasing and each year untreated kidney failure claims the lives of approximately 1 million individuals. There has been an increase in hyperphosphatemia among patients with end-stage renal disease (ESRD), thus contributing to an increase in demand for hyperphosphatemia treatment or drugs .
Competitive Landscape:
Major companies operating in the hyperphosphatemia treatment market report are Sanofi SA, Akebia Therapeutics Inc., AMAG Pharmaceuticals Inc., Ardelyx Inc., Astellas Pharma Inc., Fresenius Medical Care AG & Co. KGaA, Keryx Biopharmaceuticals Inc., Lupin Limited, Shire plc, Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Ultragenyx Pharmaceutical Inc., Unicycive Therapeutics Inc., Vifor Pharma Management Ltd., Zeria Pharmaceutical Co. Ltd., Abbott Laboratories, Amgen Inc., AstraZeneca plc, B. Braun Melsungen AG, Baxter International Inc., Beckman Coulter Inc., Cleveland Clinic, DaVita Inc., Encompass Health Corporation, FMC Corporation, Hospital Corporation of America Healthcare Inc., Kyowa Kirin Pharmaceuticals Co. Ltd., Mayo Clinic, Medtronic plc, OPKO Health Inc., Roche Diagnostics Corporation, Siemens Healthineers AG, Sysmex Corporation, Tenet Healthcare Corporation, Thermo Fisher Scientific Inc., UnitedHealth Group Inc.
Get Access To The Full Market Report -
https://www.thebusinessresearchcompany.com/report/hyperphosphatemia-treatment-global-market-report
Top Trend - Rising Emphasis On Research And Development In Hyperphosphatemia Treatment Market
The increasing research and development activities are a key trend in the hyperphosphatemia treatment market. The company in hyperphosphatemia treatment are focused on research and development activities for the development of innovative therapies for the treatment of renal diseases and related chronic conditions. For instance, in May 2021, Alebund Pharmaceuticals, a Shanghai-based biopharmaceutical company, raised $60 million in a Series B round to accelerate its development activities of innovative drugs and solutions for the treatment of renal diseases, including hyperphosphatemia.
The Table Of Content For The Market Report Include:
1. Executive Summary
2. Hyperphosphatemia Treatment Market Characteristics
3. Hyperphosphatemia Treatment Market Trends And Strategies
4. Hyperphosphatemia Treatment Market - Macro Economic Scenario
5. Hyperphosphatemia Treatment Market Size And Growth
…..
27. Hyperphosphatemia Treatment Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialize in various industries including manufacturing, healthcare, financial services, chemicals, and technology.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Hyperphosphatemia Treatment Market Analysis, Trends, Growth, Research And Forecast 2033 here
News-ID: 3400180 • Views: …
More Releases from The Business research company
Segment Evaluation and Major Growth Areas in the Personalized Testing and Supple …
The personalized testing and supplements sector is gaining remarkable traction, driven by advancements in technology and a rising consumer focus on tailored health solutions. As more individuals seek customized wellness options, this market is set to experience substantial expansion in the coming years. Here's an in-depth look at its current valuation, key players, significant trends, and the main market segments shaping its future.
Market Valuation and Expansion Forecast for Personalized Testing…
Top Players and Market Competition in the Skin Microbiome Industry
The skin microbiome market is emerging as a significant area of interest due to growing awareness about the critical role of skin health and innovative skincare technologies. As research advances and consumer preferences shift towards more natural and science-backed products, this market is set to undergo substantial growth. Let's explore the current market size, key players, driving factors, and upcoming trends shaping the skin microbiome industry.
Projected Expansion in the Skin…
Key Strategic Developments and Emerging Changes Shaping the Upadacitinib Market …
The upadacitinib market is poised for significant expansion over the coming years, driven by advances in treatment options and increasing awareness of autoimmune diseases. This report delves into the market's current size, key drivers, major players, and the emerging trends shaping its future trajectory.
Steady Growth Expected in Upadacitinib Market Size Through 2029
The market for upadacitinib is projected to reach $2.54 billion by 2029, growing at a robust compound annual…
Analysis of Key Market Segments Driving the Alzheimer's Disease Diagnostic Marke …
The Alzheimer's disease diagnostic sector is rapidly evolving as advancements in technology and healthcare infrastructure open new possibilities for early detection and personalized treatment. With rising awareness and innovative approaches, this market is poised for significant growth in the coming years. Let's explore the current market size, key drivers, leading companies, and emerging trends that are shaping this critical healthcare field.
Projected Market Size and Growth Trends in Alzheimer's Disease Diagnostics…
More Releases for Hyperphosphatemia
Hyperphosphatemia Market to Reach USD 10.3 Billion by 2034
Hyperphosphatemia is a metabolic disorder characterized by abnormally elevated phosphate levels in the blood, most often associated with chronic kidney disease (CKD) and end-stage renal disease (ESRD). When kidneys fail to excrete phosphate efficiently, it accumulates, leading to vascular calcification, bone disorders, and increased cardiovascular risk.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71967
It remains a major complication in CKD and dialysis patients, making phosphate control a critical component…
Key Trends Reshaping the Hyperphosphatemia Treatment Market: Rising Emphasis On …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Hyperphosphatemia Treatment Market Size Growth Forecast: What to Expect by 2025?
The market size for hyperphosphatemia treatment has seen a swift expansion in the recent past. The projected growth is from $4.56 billion in 2024 to $5.08 billion in 2025, reflecting a compound annual growth rate (CAGR) of 11.4%.…
Sustainable Growth Of Hyperphosphatemia Treatment Market Amid Rising Chronic Dis …
Stay ahead with our updated market reports featuring the latest on tariffs, trade flows, and supply chain transformations.
What Will the Hyperphosphatemia Treatment Industry Market Size Be by 2025?
The market for hyperphosphatemia treatment has expanded quickly in recent years. Its size is set to increase from $4.56 billion in 2024 to $5.13 billion in 2025, with a compound annual growth rate (CAGR) of 12.4%. The extension during the historical period is…
Key Influencer in the Hyperphosphatemia Treatment Market 2025: Sustainable Growt …
What industry-specific factors are fueling the growth of the hyperphosphatemia treatment market?
The rise in chronic illnesses among patients is boosting the hyperphosphatemia treatment market. Conditions like cardiovascular and kidney diseases, chronic respiratory conditions, hyperparathyroidism, diabetes, and cancer all fall under the category of chronic diseases, which are non-communicable and demand long-term management. For instance, the World Health Organization reported in September 2023 that 74% of the 41 million global deaths…
Hyperphosphatemia Pipeline Insight Report 2024
(Albany, United States) As per DelveInsight's assessment, globally, the Hyperphosphatemia Pipeline constitutes 15+ key companies continuously working towards developing 15+ Hyperphosphatemia Pipeline treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analysis DelveInsight.
In the Hyperphosphatemia Pipeline Report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, Hyperphosphatemia NDA approvals (if any), and product development activities comprising…
Hyperphosphatemia Drugs Market to Witness Robust Expansion by 2029
The Hyperphosphatemia Drugs Market size is expected to grow at an annual average of CAGR 2% during the forecast period (2023-2029). Hyperphosphatemia is characterized by an elevated level of phosphate in the blood as a result of increased intake of phosphate, migration of phosphate out of the cells, and decreased excretion of phosphate. Hyperphosphatemia is frequently found in people who suffer from chronic kidney diseases, diabetic uncontrolled diabetes, and low…
